To the Editor: Autologous progenitor cell transplantation (APCT) after a high dose of conditioning chemotherapy is now an established treatment modality for many hematological malignancies. Clinical results and survival after APCT depend on disease chemosensitivity at transplant, efficacy of the conditioning regimen, and quantity of CD34 + cells infused.
1
Most autologous progenitor cell mobilization protocols use either a combination of chemotherapy and a growth factor, 2 or a growth factor alone. 3 Mobilization failure in patients is a major therapeutic concern which makes subsequent APCT impossible. A new growth factor called plerixafor, 4 developed by the pharmaceutical industry, is especially indicated for mobilization failure.
In this context, we report the first experience of the use of plerixafor for CD34 + mobilization in Algeria.
A total of 221 autografts were performed at our center from May 2009-31 July 2014. The main indications for autograft were multiple myeloma (MM) (148 patients), Hodgkin's lymphoma (HL) (60 patients), and non-Hodgkin's lymphoma (NHL) (13 patients). The mobilization protocol involved subcutaneous G-CSF (filgrastim) alone at the dose of 15 lg/kg body weight/day for five days. Mobilization failure is declared when the number of CD34 + is less than 2.10 6 /kg body weight. Thirteen patients did not mobilize CD34 + . With patients experiencing mobilization failure, we used plerixafor at 0.24 mg/kg body weight combined with G-CSF. Harvesting took place six to ten hours after plerixafor injection. Mobilization failure during APCT is a major concern in the therapeutic management of patients with hematological malignancies. In our series of 13 patients, mobilization failure with + count four fold and to salvage almost 70% of cases of primary mobilization failure with a single injection for most patients (n = 8) and two injections for one patient.
In conclusion, our experience in the use of plerixafor enabled us to show effectiveness in autologous progenitor cell mobilization with a salvage rate of almost 70%.
